Harrow Health (NASDAQ:HROW) Director Sells $34,125.00 in Stock
Harrow Health (NASDAQ:HROW) Director Robert J. Kammer sold 6,500 shares of Harrow Health stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $5.25, for a total transaction of $34,125.00.
Shares of NASDAQ:HROW traded down $0.04 during trading on Wednesday, reaching $5.12. The stock had a trading volume of 3,199 shares, compared to its average volume of 265,207. Harrow Health has a 52 week low of $2.22 and a 52 week high of $8.99. The business’s 50-day moving average price is $5.52 and its 200 day moving average price is $5.97. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.87 and a quick ratio of 3.60. The stock has a market capitalization of $137.41 million, a PE ratio of 8.37 and a beta of 0.14.
Harrow Health (NASDAQ:HROW) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Harrow Health had a return on equity of 50.32% and a net margin of 51.32%. The company had revenue of $13.52 million during the quarter, compared to the consensus estimate of $12.55 million. Analysts forecast that Harrow Health will post -0.06 EPS for the current year.
A number of research firms have recently issued reports on HROW. Zacks Investment Research upgraded shares of Harrow Health from a “sell” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Friday, September 6th. Lake Street Capital set a $15.00 target price on shares of Harrow Health and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, ValuEngine upgraded shares of Harrow Health from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 11th.
About Harrow Health
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
Recommended Story: Day Trading
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.